Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $209000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities fell 33.65% year-over-year to $209000.0, compared with a TTM value of $209000.0 through Dec 2025, down 33.65%, and an annual FY2025 reading of $209000.0, down 33.65% over the prior year.
  • Other Non-Current Liabilities was $209000.0 for Q4 2025 at Catalyst Pharmaceuticals, up from $161000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $14.7 million in Q3 2022 and bottomed at $161000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 4 years is $5.0 million, with a median of $2.7 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities decreased 22.1% in 2024, then plummeted 94.22% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $14.1 million in 2022, then crashed by 78.8% to $3.0 million in 2023, then plummeted by 89.44% to $315000.0 in 2024, then tumbled by 33.65% to $209000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CPRX at $209000.0 in Q4 2025, $161000.0 in Q3 2025, and $309000.0 in Q2 2025.